Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sirt7 siRNA
- Development stage
- Preclinical
- Lead developer
- Sigma Aldrich
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Parenteral
01
Overview
Sirt7 siRNA is a research-stage RNA interference (RNAi) reagent designed to silence or knock down the expression of the SIRT7 (Sirtuin 7) gene. SIRT7 is a member of the sirtuin family of NAD+-dependent deacylases that plays a critical role in epigenetic regulation, DNA damage response, aging, and cancer progression. By utilizing small interfering RNA (siRNA) to target and degrade SIRT7 mRNA, researchers use this tool to study the protein's involvement in various malignancies, including hepatocellular carcinoma, breast cancer, and osteosarcoma, as well as its impact on metabolic pathways like the insulin/IGF-1 signaling axis. Sirt7 siRNA is not a proprietary clinical drug but is widely available from commercial reagent suppliers such as Sigma-Aldrich and Santa Cruz Biotechnology for preclinical laboratory investigations.
- Other names
- SIRT7 small interfering RNASIRT-7 small interfering RNASIRT 7 small interfering RNASirtuin 7 siRNASirtuin7 siRNASirtuin-7 siRNAsiSIRT7siSIRT-7siSIRT 7
02
Targets
SIRT7 (Sirtuin 7)
Beyond the preview
Go deeper on Sirt7 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sirt7 siRNA.